Anupam Rasayan India Credit Rating Remains on Watch Following Acquisition News

Crisil Ratings has maintained its 'Rating Watch with Developing Implications' for Anupam Rasayan India’s bank facilities of Rs 1,620 crore and Rs 160 crore in NCDs. The agency confirms the current rating stands at Crisil A+ for long-term instruments and Crisil A1 for short-term facilities.

Reader Takeaway: Ratings watch continues pending funding clarity for Bliss GVS Pharma acquisition; final impact expected within one notch.

What just happened

The credit rating agency is monitoring the proposed acquisition of a 43.3% to 48.2% equity stake in Bliss GVS Pharma. Crisil notes that the 'Watch' status is a precautionary measure to assess the impact of this transaction, which is slated for completion in September 2026. The rating agency intends to lift the watch once it evaluates the final capital structure and funding mix.

Why this matters

For investors, the rating status signals ongoing oversight of the company's leverage. Anupam Rasayan plans to raise Rs 300 crore in fresh debt to support the acquisition, with the remainder funded by a global investment management firm through non-voting, non-controlling equity. Crisil has stated that any resulting change to the current rating is unlikely to exceed a single notch, providing a degree of stability for bondholders and lenders.

Financial Context

In FY2026, the company recorded operating income of Rs 2,365.46 crore, up from Rs 1,438.72 crore in the previous year. However, profitability saw pressure, with PAT margins contracting to 9.39% from 11.11% in FY2025. The agency attributed this margin compression to the company’s limited ability to pass on elevated input costs to customers.

Risks to watch

Beyond the acquisition-related funding, the company continues to manage working-capital intensive operations. Crisil highlights that the company remains susceptible to volatility in foreign exchange rates and fluctuating raw material prices, which could impact future operating margins.